Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.38 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18723160 | 1.00 | IRAK4 (0.41) | IRAK4APLNRSMPD1PLA2G4ACDC7 | |
| SCHEMBL16065162 | 0.93 | IRAK4 (0.37) | IRAK4APLNRCDC7DBF4CYP1A2 | |
| SCHEMBL16065256 | 0.90 | SMPD1 (0.41) | IRAK4SMPD1 | |
| SCHEMBL16065155 | 0.90 | APLNR (0.37) | IRAK4APLNRCDC7DBF4CYP1A2 | |
| SCHEMBL16065156 | 0.90 | IRAK4 (0.38) | IRAK4CDC7DBF4CYP1A2NLRP3 | |
| SCHEMBL16065096 | 0.88 | IRAK4 (0.37) | IRAK4APLNRCDC7DBF4CYP1A2 | |
| SCHEMBL20170987 | 0.88 | IRAK4 (0.35) | IRAK4APLNRCDC7DBF4CYP1A2 | |
| SCHEMBL18723161 | 0.88 | IRAK4 (0.41) | IRAK4SMPD1 | |
| SCHEMBL17407018 | 0.88 | IRAK4 (0.41) | IRAK4SMPD1 | |
| SCHEMBL26706283 | 0.85 | IRAK4 (0.45) | IRAK4APLNRCDC7DBF4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617282-B2 | Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases | BIOGEN MA INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160002265-A1 | MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN MA INC. (US) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002265-A1 | MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885APLNR 2695/4885SMPD1 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.